ABSTRACT
OBJECTIVES: To test the usefulness of an extended panel of lymphocyte subsets in combination with Oliveira's diagnostic criteria for the identification of autoimmune lymphoproliferative syndrome (ALPS) in children referred to a paediatric rheumatology centre. METHODS: Patients referred from 2015 to 2018 to our rheumatology unit for an autoimmune or autoinflammatory condition were retrospectively analysed. Oliveira's required criteria [chronic lymphoproliferation and elevated double-negative T (DNT)] were applied as first screening. Flow cytometry study included double-negative CD4-CD8-TCRαß+ T lymphocytes (DNT), CD25+CD3+, HLA-DR+CD3+ T cells, B220+ T cells and CD27+ B cells. Data were analysed with a univariate logistic regression analysis, followed by a multivariate analysis. Sensitivity and specificity of the Oliveira's required criteria were calculated. RESULTS: A total of 264 patients were included in the study and classified as: (i) autoimmune diseases (n = 26); (ii) juvenile idiopathic arthritis (JIA) (35); (iii) monogenic systemic autoinflammatory disease (27); (iv) periodic fever, aphthous stomatitis, pharyngitis and adenitis syndrome (100); (v) systemic undefined recurrent fever (45); (vi) undetermined-systemic autoinflammatory disease (14); or (vii) ALPS (17). Oliveira's required criteria displayed a sensitivity of 100% and specificity of 79%. When compared with other diseases the TCRαß+B220+ lymphocytes were significantly increased in ALPS patients. The multivariate analysis revealed five clinical/laboratory parameters positively associated to ALPS: splenomegaly, female gender, arthralgia, elevated DNT and TCRαß+B220+ lymphocytes. CONCLUSIONS: Oliveira's required criteria are useful for the early suspicion of ALPS. TCRαß+B220+ lymphocytes should be added in the diagnostic work-up of patients referred to the paediatric rheumatology unit for a suspected autoimmune or autoinflammatory condition, providing a relevant support in the early diagnosis of ALPS.
Subject(s)
Autoimmune Diseases/diagnosis , Autoimmune Lymphoproliferative Syndrome/diagnosis , Hereditary Autoinflammatory Diseases/diagnosis , Age of Onset , Autoimmune Diseases/blood , Autoimmune Lymphoproliferative Syndrome/blood , CD4-CD8 Ratio , Child , Child, Preschool , Early Diagnosis , Female , Flow Cytometry , Hereditary Autoinflammatory Diseases/blood , Humans , Infant , Male , Receptors, Antigen, T-Cell, alpha-beta/blood , Retrospective StudiesABSTRACT
BACKGROUND: Mutations along PSTPIP1 gene are associated to two specific conditions, PAPA syndrome and PAMI syndrome, both autoinflammatory disorders associated to disturbances in cytoskeleton formation. Immunological aspects of PAMI syndrome has not yet been reported neither the clinical impact on therapeutical decisions. METHODS: Clinical data of patients records were retrospectively accessed. Genomic DNA were extracted and sequenced following standard procedures. Peripheral lymphocytes were quantified in T, B e FOXP3 phenotypes. RESULTS: We describe two related patients with PAMI syndrome harboring the usual E250K mutation. Anti-IL1 therapy could partially control the disease in the index patient. A broad spectrum of immunological effects as well as an aberrant expression of FOXP3 could be observed. CONCLUSIONS: Here we report two related brazilian patients with PAMI syndromes harboring the E250K mutation in PSTPIP1, their immunological aspects and the therapeutical response to canakinumab.
Subject(s)
Adaptor Proteins, Signal Transducing/genetics , Anemia , Antibodies, Monoclonal, Humanized/administration & dosage , Cytoskeletal Proteins/genetics , Hereditary Autoinflammatory Diseases , Interleukin-1beta , Neutropenia , Adult , Anemia/diagnosis , Anemia/etiology , Blood Transfusion/methods , C-Reactive Protein/analysis , Child, Preschool , Female , Hereditary Autoinflammatory Diseases/blood , Hereditary Autoinflammatory Diseases/genetics , Hereditary Autoinflammatory Diseases/physiopathology , Hereditary Autoinflammatory Diseases/therapy , Humans , Immunologic Tests/methods , Immunophenotyping/methods , Interleukin-1beta/antagonists & inhibitors , Interleukin-1beta/immunology , Monitoring, Immunologic/methods , Mutation , Neutropenia/diagnosis , Neutropenia/etiology , Steroids/administration & dosage , Symptom Flare Up , Treatment OutcomeSubject(s)
Arthritis , Hearing Loss, Sensorineural , Hereditary Autoinflammatory Diseases , Myelodysplastic Syndromes/diagnosis , Scleritis , Ubiquitin-Activating Enzymes/genetics , Acute-Phase Proteins/analysis , Anemia, Macrocytic/diagnosis , Anemia, Macrocytic/etiology , Arthritis/diagnosis , Arthritis/etiology , Diagnosis, Differential , Female , Hearing Loss, Sensorineural/diagnosis , Hearing Loss, Sensorineural/etiology , Hereditary Autoinflammatory Diseases/blood , Hereditary Autoinflammatory Diseases/diagnosis , Hereditary Autoinflammatory Diseases/genetics , Hereditary Autoinflammatory Diseases/physiopathology , Humans , Middle Aged , Mutation , Myeloid Progenitor Cells/pathology , Scleritis/diagnosis , Scleritis/etiology , Symptom Assessment , VacuolesABSTRACT
Objectives: Genetic analysis of TNFRSF1A can confirm the diagnosis of tumor necrosis factor receptor-associated periodic syndrome (TRAPS), but interpretation of the pathogenesis of variants of unknown significance is sometimes required. The aim of this study was to evaluate the clinical significance of serum soluble tumor necrosis factor receptor type I (sTNFR-I)/II ratio to differentiate TRAPS from other autoinflammatory diseases. Methods: Serum sTNFR-I and sTNFR-II levels were measured using an enzyme-linked immunosorbent assay in patients with TRAPS (n = 5), familial Mediterranean fever (FMF) (n = 14), systemic juvenile idiopathic arthritis (s-JIA) (n = 90), and Kawasaki disease (KD) (n = 37) in the active and inactive phase, along with healthy controls (HCs) (n = 18). Results: In the active phase, the serum sTNFR-I/II ratio in patients with s-JIA, KD, and FMF was significantly elevated compared with that in HCs, whereas it was not elevated in patients with TRAPS. In the inactive phase, the serum sTNFR-I/II ratio in patients with s-JIA and FMF was significantly higher compared with that in HCs, and the ratio was lower in TRAPS patients than in patients with s-JIA and FMF. Conclusions: Low serum sTNFR-I/II ratio in the active and inactive phase might be useful for the differential diagnosis of TRAPS and other autoinflammatory diseases.
Subject(s)
Enzyme-Linked Immunosorbent Assay , Familial Mediterranean Fever/diagnosis , Fever/diagnosis , Hereditary Autoinflammatory Diseases/diagnosis , Hyaline Fibromatosis Syndrome/diagnosis , Mucocutaneous Lymph Node Syndrome/diagnosis , Receptors, Tumor Necrosis Factor, Type II/blood , Receptors, Tumor Necrosis Factor, Type I/blood , Adolescent , Adult , Biomarkers/blood , Case-Control Studies , Child , Child, Preschool , Diagnosis, Differential , Familial Mediterranean Fever/blood , Familial Mediterranean Fever/immunology , Female , Fever/blood , Fever/immunology , Hereditary Autoinflammatory Diseases/blood , Hereditary Autoinflammatory Diseases/immunology , Humans , Hyaline Fibromatosis Syndrome/blood , Hyaline Fibromatosis Syndrome/immunology , Infant , Infant, Newborn , Male , Middle Aged , Mucocutaneous Lymph Node Syndrome/blood , Mucocutaneous Lymph Node Syndrome/immunology , Predictive Value of Tests , Young AdultABSTRACT
Objective: Monogenic autoinflammatory diseases (AIDs) are inborn disorders caused by innate immunity dysregulation and characterized by robust autoinflammation. We aimed to present the phenotypes and genotypes of Chinese pediatric monogenic AID patients. Methods: A total of 288 pediatric patients clinically suspected to have monogenic AIDs at the Department of Pediatrics of Peking Union Medical College Hospital between November 2008 and May 2019 were genotyped by Sanger sequencing, and/or gene panel sequencing and/or whole exome sequencing. Final definite diagnoses were made when the phenotypes and genotypes were mutually verified. Results: Of the 288 patients, 79 (27.4%) were diagnosed with 18 kinds of monogenic AIDs, including 33 patients with inflammasomopathies, 38 patients with non-inflammasome related conditions, and eight patients with type 1 interferonopathies. Main clinical features were skin disorders (76%), musculoskeletal problems (66%), fever (62%), growth retardation (33%), gastrointestinal tract abnormalities (25%), central nervous system abnormalities (15%), eye disorders (16%), ear problems (9%), and cardiopulmonary disorders (8%). The causative genes were ACP5, ADA2, ADAR1, IFIH1, LPIN2, MEFV, MVK, NLRC4, NLRP3, NLRP12, NOD2, PLCG2, PSMB8, PSTPIP1, TMEM173, TNFAIP3, TNFRSF1A, and TREX1. Conclusions: The present study summarized both clinical and genetic characteristics of 18 kinds of monogenic AIDs found in the largest pediatric AID center over the past decade, with fever, skin problems, and musculoskeletal system disorders being the most prevalent clinical features. Many of the mutations were newly discovered. This is by far the first and largest monogenic AID report in Chinese pediatric population and also a catalog of the phenotypic and genotypic features among these patients.
Subject(s)
Genotype , Hereditary Autoinflammatory Diseases/genetics , Immunity, Innate/genetics , Mutation , Phenotype , Adolescent , Child , Child, Preschool , China/epidemiology , Cohort Studies , Female , Genes , Hereditary Autoinflammatory Diseases/blood , Hereditary Autoinflammatory Diseases/epidemiology , Humans , Infant , Infant, Newborn , Inflammasomes/genetics , Male , Exome SequencingABSTRACT
BACKGROUND: Deficiency of the natural antagonist of interleukin-1 was first described in 2009 and so far 20 patients has been reported. In Brazil just two cases have been reported both carrying the same homozygous 15 bp deletion. Blocking interleukin-1 has changed rate survival for DIRA patients. The use of anakinra and rilonacept has been reported safe and efficient, whereas the selective blockade of interleukin-1 beta, using the monoclonal antibody canakinumab has been reported in a single case only. CASE PRESENTATION: Here we report a case of a 7 years old Brazilian boy that presented with recurrent episodes of systemic inflammation with severe disabling osteomyelitis with mild pustular skin rash. A Next Generation Sequencing gene panel allowed to detect two pathogenic mutations in the IL1RN gene, described in compound heterozygosity. Corticosteroids was effective in controlling inflammation and anti-IL1 beta blocker triggered disease flare. Complete clinical control could be achieved using IL-1 receptor antagonist. CONCLUSIONS: DIRA is a severe, life threatening autoinflammatory condition with low numbers of patients described all over the world. The mutation p.Asp72_Ile76del in IL1RN is presented in all Brazilian DIRA patients already described and p.Q45* (rs1019766125) is a new mutation affecting the IL1RN gene. Following the pathogenesis of DIRA, blocking both subunits of interleukin one as well as antagonizing the receptor using anakinra or rilonacept seems to be effective. There is just one report using canakinumab for the treatment of DIRA and this is the first report of disease flare using this drug.
Subject(s)
Adrenal Cortex Hormones/administration & dosage , Antibodies, Monoclonal, Humanized , Genetic Testing/methods , Hereditary Autoinflammatory Diseases , Interleukin 1 Receptor Antagonist Protein , Interleukin-1beta/genetics , Osteomyelitis , Antibodies, Monoclonal, Humanized/administration & dosage , Antibodies, Monoclonal, Humanized/adverse effects , Antirheumatic Agents/administration & dosage , Antirheumatic Agents/adverse effects , Child , Hereditary Autoinflammatory Diseases/blood , Hereditary Autoinflammatory Diseases/drug therapy , Hereditary Autoinflammatory Diseases/genetics , Hereditary Autoinflammatory Diseases/physiopathology , Homozygote , Humans , Interleukin 1 Receptor Antagonist Protein/administration & dosage , Interleukin 1 Receptor Antagonist Protein/adverse effects , Interleukin 1 Receptor Antagonist Protein/blood , Interleukin 1 Receptor Antagonist Protein/genetics , Mutation , Osteomyelitis/diagnostic imaging , Osteomyelitis/physiopathology , Osteomyelitis/therapy , Radiography/methods , Symptom Flare Up , Treatment OutcomeSubject(s)
Adenosine Deaminase/deficiency , Hereditary Autoinflammatory Diseases/complications , Intercellular Signaling Peptides and Proteins/deficiency , Polyarteritis Nodosa/diagnosis , Adenosine Deaminase/blood , Adenosine Deaminase/genetics , Adolescent , Adult , Biopsy , Child , Hereditary Autoinflammatory Diseases/blood , Hereditary Autoinflammatory Diseases/diagnosis , Hereditary Autoinflammatory Diseases/genetics , Humans , Intercellular Signaling Peptides and Proteins/blood , Intercellular Signaling Peptides and Proteins/genetics , Polyarteritis Nodosa/blood , Polyarteritis Nodosa/genetics , Polyarteritis Nodosa/pathology , Retrospective Studies , Skin/pathology , Young AdultABSTRACT
BACKGROUND: Serum phagocyte-derived alarmins S100A8/9 and S100A12 are considered useful for the assessment of inflammatory diseases. Our study evaluated the use of S100 proteins in a pediatric clinical setting for estimating disease activity and supporting diagnosis. METHODS: Patients (n = 136) who had S100 proteins tested as part of clinical care were included in this study and relevant information obtained from the medical record: C-reactive protein (CRP), disease activity status (inactive: = 0 joint; active: > 0 active joint), systemic symptoms in systemic JIA (sJIA), and symptoms of flare of other autoinflammatory and fever syndromes. Patients were categorized as: sJIA, non-systemic JIA (nsJIA), other defined autoinflammatory syndromes (AID) and systemic undifferentiated recurring fever syndromes (SURFS). RESULTS: Patients with sJIA (n = 21) had significantly higher levels of S100A8/9 and S100A12 compared to patients with nsJIA (n = 49), other AIDs (n = 8) or SURFS (n = 14) (all p < 0.0001). Compared to CRP [area under the receiver operating characteristics curve (AUC) = 0.7], S100 proteins were superior in differentiating sJIA from AID and SURFS [AUC = 0.9]. S100A8/9 and S100A12 levels were not associated with disease activity in nsJIA, AID or SURFS. S100A8/9 and S100A12 levels were significantly higher in active sJIA compared to inactive (p = 0.0002 and p = 0.0002 respectively). CONCLUSION: Compared to other autoinflammatory and fever syndromes, sJIA patients have markedly higher levels of S100A8/9 and S100A12 proteins which may assist with diagnosis. S100 levels slightly outperformed CRP in distinguishing sJIA from other diagnoses and in sJIA disease activity. S100 proteins may aid in monitoring disease activity in sJIA patients.
Subject(s)
Arthritis, Juvenile/diagnosis , Hereditary Autoinflammatory Diseases/diagnosis , S100 Proteins/blood , Arthritis, Juvenile/blood , Biomarkers/blood , Calgranulin A/blood , Calgranulin B/blood , Cross-Sectional Studies , Hereditary Autoinflammatory Diseases/blood , Humans , Retrospective Studies , S100A12 Protein/blood , Sensitivity and Specificity , Severity of Illness IndexABSTRACT
We identified a consanguineous kindred, of three affected children with severe autoinflammation, resulting in the death of one sibling and allogeneic stem cell transplantation in the other two. All three were homozygous for MEFV p.S208C mutation; however, their phenotype was more severe than previously reported, prompting consideration of an oligogenic autoinflammation model. Further genetic studies revealed homozygous mutations in TRAP1, encoding the mitochondrial/ER resident chaperone protein tumour necrosis factor receptor associated protein 1 (TRAP1). Identification of a fourth, unrelated patient with autoinflammation and compound heterozygous mutation of TRAP1 alone facilitated further functional studies, confirming the importance of this protein as a chaperone of misfolded proteins with loss of function, which may contribute to autoinflammation. Impaired TRAP1 function leads to cellular stress and elevated levels of serum IL-18. This study emphasizes the importance of considering digenic or oligogenic models of disease in particularly severe phenotypes and suggests that autoinflammatory disease might be enhanced by bi-allelic mutations in TRAP1.
Subject(s)
HSP90 Heat-Shock Proteins/genetics , Hereditary Autoinflammatory Diseases/genetics , Mutation , Phenotype , Adolescent , Adult , Child , Child, Preschool , Consanguinity , Fatal Outcome , Female , Follow-Up Studies , Hematopoietic Stem Cell Transplantation/methods , Hereditary Autoinflammatory Diseases/blood , Hereditary Autoinflammatory Diseases/therapy , Humans , Infant , Infant, Newborn , Interleukin-18/blood , Male , Pedigree , Pyrin/genetics , Transplantation, Homologous , Treatment Outcome , Young AdultABSTRACT
AIM: The syndrome of periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) is a common inflammatory disease that presents with periodic fever. We aimed to establish more specific diagnostic criteria for PFAPA based on the clinical characteristics of PFAPA patients in our directory. METHOD: The clinical, laboratory, genetic, and family history details of 257 Japanese PFAPA patients treated at our and other affiliated hospitals between April 2000 and April 2018 were analyzed along with quantitative measurements of the number of CD64 molecules on neutrophils, and the levels of serum inflammatory cytokines. The sensitivity and specificity of the criteria were calculated for several diseases. RESULTS: Because recurrent fevers were crucial findings, they were defined as the required criterion. Tonsillitis/pharyngitis with white moss were important accompanying signs. Other symptoms associated with febrile episodes were cervical lymphadenitis with tenderness, aphthous stomatitis, sore throat, vomiting, and headache but not cough. A total of 159 (62%) patients had a family history of recurrent fevers, indicating autosomal dominant inheritance. C-reactive protein levels were extremely elevated during febrile attacks but normal in attack-free periods. Serum immunoglobulin D levels were high in 72 of the 199 tested patients. Oral glucocorticoid and cimetidine were extremely effective in all and 51.6% of the patients, respectively. We defined the above as supportive criteria. These criteria were sensitive and specific enough to distinguish PFAPA from other recurrent fever diseases. Raised serum interferon-γ levels and remarkable CD64 expression on neutrophils during flare-ups were recognized, indicating they contributed to diagnosis. CONCLUSION: Our new criteria are useful for diagnosing PFAPA.
Subject(s)
Fever/diagnosis , Hereditary Autoinflammatory Diseases/diagnosis , Lymphadenitis/diagnosis , Pharyngitis/diagnosis , Stomatitis, Aphthous/diagnosis , Biomarkers/blood , Child, Preschool , Cytokines/blood , Female , Fever/blood , Fever/immunology , Fever/therapy , Glucocorticoids/therapeutic use , Hereditary Autoinflammatory Diseases/blood , Hereditary Autoinflammatory Diseases/immunology , Hereditary Autoinflammatory Diseases/therapy , Heredity , Histamine H2 Antagonists/therapeutic use , Humans , Infant , Inflammation Mediators/blood , Japan , Lymphadenitis/blood , Lymphadenitis/immunology , Lymphadenitis/therapy , Male , Membrane Cofactor Protein/blood , Neutrophils/immunology , Pedigree , Pharyngitis/blood , Pharyngitis/immunology , Pharyngitis/therapy , Predictive Value of Tests , Reproducibility of Results , Stomatitis, Aphthous/blood , Stomatitis, Aphthous/immunology , Stomatitis, Aphthous/therapy , Syndrome , Tonsillectomy , Treatment OutcomeABSTRACT
OBJECTIVE: The periodic fever, aphthous stomatitis, pharangytis and cervical adenitis (PFAPA) syndrome, is an idiopathic chronic disease of non-hereditary origin, primarily affecting pre-school children and is the most common periodic fever disorder in children. Rapid response to corticosteroid treatment suggest an immune dysregulation. Recently, emerging evidence suggest that vitamin D plays an important role in immunity regulation. The aim of our study was to assess the vitamin D levels in children with PFAPA syndrome. METHODS: This study was conducted prospectively. We have consecutively evaluated 50 patients after having excluded other causes of recurrent fever between May 2017 and May 2018 in addition to age-matched 50 patients as control group. All patients has complete physical examination and laboratory tests. Laboratory tests included complete blood count, C-reactive protein (CRP), and vitamin D levels. Serum 25 (OH) vitamin D levels were measured in all patients twice yearly. RESULTS: Vitamin D levels was 18⯱â¯10â¯ng/ml in the patient group and 35⯱â¯13â¯ng/ml in the control group. There was statistically significant difference between the groups (pâ¯<â¯0.001). 38 patients from the PFAPA group and 20 patients from the control group had low vitamin D levels. Multivariate logistic regression analysis showed that CRP (odd ratio (OR)â¯=â¯2.7, 95% confidence interval (CI)â¯=â¯2.4-4.1) and serum 25 (OH) vitamin D levels <30â¯ng/ml ORâ¯=â¯2.1, 95% CIâ¯=â¯1.8-2.5) were associated with PFAPA occurrence. CONCLUSION: We found strong correlation between PFAPA and vitamin D insufficiency. Hypovitaminosis D can be a significant risk factor for PFAPA episode recurrence.
Subject(s)
Hereditary Autoinflammatory Diseases/blood , Vitamin D Deficiency/complications , Vitamin D/blood , Blood Cell Count , C-Reactive Protein/analysis , Child , Child, Preschool , Female , Hereditary Autoinflammatory Diseases/etiology , Humans , Male , Prospective Studies , Risk Factors , Syndrome , Vitamin D Deficiency/bloodABSTRACT
BACKGROUND: Autoinflammatory disorders are distinguished by seemingly random episodes of systemic hyperinflammation, driven in particular by IL-1. Recent pre-clinical work has shown a key role for IL-1 in epilepsy in animal models, and therapies for autoinflammation including IL-1 blockade are proposed for refractory epilepsy. CASE PRESENTATION: Here, we report an adolescent female with signs of persistent systemic inflammation and epilepsy unresponsive to multiple anti-epileptic drugs (AED). She was diagnosed with generalized epilepsy with a normal brain MRI and an electroencephalogram (EEG) showing occasional generalized spike and slow wave discharges. Her diagnostic evaluation showed no signs of autoimmunity or genetic causes of epilepsy or periodic fever syndromes but persistently elevated serum inflammatory markers including S100 alarmin proteins. She experienced prompt clinical response to IL-1 blockade with first anakinra and then canakinumab, with near complete resolution of clinical seizures. Additionally, she displayed marked improvements in quality of life and social/academic functioning. Baseline gene expression studies on peripheral blood mononuclear cells (PBMC) from this patient showed significantly activated gene pathways suggesting systemic immune activation, including focal adhesion, platelet activation, and Rap1 signaling, which is an upstream regulator of IL-1ß production by the NLRP3 inflammasome. It also showed activation of genes that characterize inflammasome-mediated autoinflammatory disorders and no signs of interferon activation. This gene expression signature was largely extinguished after anakinra treatment. CONCLUSIONS: Together, these findings suggest that patients with epilepsy responsive to immune modulation may have distinct autoinflammatory features supporting IL-1 blockade. As such, IL-1 blockade may be highly efficacious adjunctive medication for certain refractory epilepsy syndromes.
Subject(s)
Drug Resistant Epilepsy/complications , Drug Resistant Epilepsy/drug therapy , Hereditary Autoinflammatory Diseases/complications , Hereditary Autoinflammatory Diseases/drug therapy , Interleukin-1/antagonists & inhibitors , Adolescent , Antibodies, Monoclonal/pharmacology , Antibodies, Monoclonal/therapeutic use , Antibodies, Monoclonal, Humanized , Drug Resistant Epilepsy/blood , Female , Hereditary Autoinflammatory Diseases/blood , Humans , Interleukin 1 Receptor Antagonist Protein/pharmacology , Interleukin 1 Receptor Antagonist Protein/therapeutic use , Interleukin-1/blood , Leukocytes, Mononuclear/drug effects , Leukocytes, Mononuclear/metabolismABSTRACT
Microbial nucleic acid recognition serves as the major stimulus to an antiviral response, implying a requirement to limit the misrepresentation of self nucleic acids as non-self and the induction of autoinflammation. By systematic screening using a panel of interferon-stimulated genes we identify two siblings and a singleton variably demonstrating severe neonatal anemia, membranoproliferative glomerulonephritis, liver fibrosis, deforming arthropathy and increased anti-DNA antibodies. In both families we identify biallelic mutations in DNASE2, associated with a loss of DNase II endonuclease activity. We record increased interferon alpha protein levels using digital ELISA, enhanced interferon signaling by RNA-Seq analysis and constitutive upregulation of phosphorylated STAT1 and STAT3 in patient lymphocytes and monocytes. A hematological disease transcriptomic signature and increased numbers of erythroblasts are recorded in patient peripheral blood, suggesting that interferon might have a particular effect on hematopoiesis. These data define a type I interferonopathy due to DNase II deficiency in humans.
Subject(s)
Deoxyribonucleases/deficiency , Endodeoxyribonucleases/deficiency , Hereditary Autoinflammatory Diseases/enzymology , Interferon-alpha/immunology , Signal Transduction/immunology , Adolescent , Antiviral Agents/pharmacology , Child , Deoxyribonucleases/genetics , Deoxyribonucleases/immunology , Endodeoxyribonucleases/genetics , Endodeoxyribonucleases/immunology , Erythroblasts/immunology , Female , Gene Expression Profiling , Hematopoiesis/immunology , Hereditary Autoinflammatory Diseases/blood , Hereditary Autoinflammatory Diseases/genetics , Hereditary Autoinflammatory Diseases/immunology , Humans , Interferon-alpha/blood , Interferon-alpha/metabolism , Male , Mutation , Phosphorylation , RNA, Messenger/analysis , STAT1 Transcription Factor/metabolism , STAT3 Transcription Factor/metabolism , Sequence Analysis, RNA , Up-Regulation/drug effectsABSTRACT
OBJECTIVE: Pyrin-Associated Autoinflammation with Neutrophilic Dermatosis (PAAND) is a recently described monogenic autoinflammatory disease. The causal p.S242R MEFV mutation disrupts a binding motif of the regulatory 14-3-3 proteins within pyrin. Here, we investigate a family with clinical features consistent with PAAND in whom the novel p.E244K MEFV mutation, located in the +2 site of the 14-3-3 binding motif in pyrin, has been found. METHODS: Multiplex cytokine analyses were performed on p.E244K patient and control serum. Peripheral blood mononuclear cells were stimulated ex vivo with lipopolysaccharide (LPS). In vitro, inflammasome complex formation was evaluated by flow cytometry of Apoptosis-associated Speck-like protein containing a Caspase recruitment domain (ASC) specks. Interleukin-1ß (IL-1ß) and IL-18 production was quantified by ELISA. The ability of the p.E244K pyrin mutation to interact with 14-3-3 was assessed by immunoprecipitation. RESULTS: PAAND p.E244K patient serum displayed a different cytokine profile compared with patients with Familial Mediterranean Fever (FMF). In overexpression models, p.E244K pyrin was associated with decreased 14-3-3 binding and increased ASC speck formation. THP-1 monocytes expressing PAAND pyrin mutations demonstrated spontaneous caspase-1-dependent IL-1ß and IL-18 secretion, as well as cell death, which were significantly greater than those of wild-type and the FMF-associated mutation p.M694V. CONCLUSION: In PAAND, disruption of the +2 position of a 14-3-3 binding motif in pyrin results in its constitutive activation, with spontaneous production of IL-1ß and IL-18, associated with inflammatory cell death. The altered serum cytokine profile may explain the different clinical features exhibited by PAAND patients compared with those with FMF.
Subject(s)
14-3-3 Proteins/blood , Familial Mediterranean Fever/blood , Hereditary Autoinflammatory Diseases/blood , Pyrin/blood , Sweet Syndrome/blood , Case-Control Studies , Caspase 1/metabolism , Cytokines/blood , Diagnosis, Differential , Familial Mediterranean Fever/diagnosis , Familial Mediterranean Fever/genetics , Flow Cytometry , Hereditary Autoinflammatory Diseases/diagnosis , Hereditary Autoinflammatory Diseases/genetics , Humans , Leukocytes, Mononuclear/metabolism , Lipopolysaccharides/administration & dosage , Mutation , Protein Binding , Sweet Syndrome/diagnosis , Sweet Syndrome/geneticsSubject(s)
Fever/blood , Hereditary Autoinflammatory Diseases/blood , Intercellular Adhesion Molecule-1/blood , Adult , Biomarkers/blood , Case-Control Studies , Female , Fever/diagnosis , Fever/genetics , Genetic Predisposition to Disease , Hereditary Autoinflammatory Diseases/diagnosis , Hereditary Autoinflammatory Diseases/genetics , Humans , Male , Middle Aged , Mutation , Phenotype , Receptors, Tumor Necrosis Factor, Type I/genetics , Up-RegulationSubject(s)
Anti-Mullerian Hormone/blood , Hereditary Autoinflammatory Diseases , Ovarian Reserve/immunology , Adult , Case-Control Studies , Female , Germany/epidemiology , Hereditary Autoinflammatory Diseases/blood , Hereditary Autoinflammatory Diseases/ethnology , Hereditary Autoinflammatory Diseases/physiopathology , Humans , Interleukin-1/blood , Research Design , Statistics as TopicABSTRACT
Periodic fevers are acquired or inherited disorders of innate immunity, which were first described in the 1940s. The patients are typically young at onset and have regularly recurring fevers for a few days to a few weeks with systemic inflammatory symptoms that are interrupted by symptom-free periods. There is a variety of clinical manifestations including gastrointestinal complaints, myalgias, arthralgias, and rash. A differential diagnosis in these patients may include recurrent infections, other inflammatory disorders, and neoplastic disease. This clinical review focuses on a sample of autoinflammatory disorders including familial Mediterranean fever, tumor necrosis factor receptor 1-associated periodic syndrome, hyperimmunoglobulinemia D syndrome, the cryopyrin-associated periodic syndrome, and periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis syndrome. We review the basics, pertinent clinical and laboratory features, and management of each entity.